Xiamen Amoytop Biotech Co., Ltd.

Quick facts

Marketed products

• rhG-CSF+rhGM-CSF group · Oncology; Hematology
  This combination of recombinant human granulocyte colony-stimulating factor (rhG-CSF) and recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) stimulates the production and activation of neutrophils and myeloid cells to enhance immune function and hematopoietic recovery.

Phase 3 pipeline

• Inpegsomatropin Injection · Endocrinology
  Inpegsomatropin is a long-acting growth hormone analog that binds to growth hormone receptors to promote growth, metabolism, and body composition changes.
• rhG-CSF/PEG-rhG-CSF · Oncology
  rhG-CSF/PEG-rhG-CSF stimulates the production of white blood cells.
• YPEG-rhG-CSF · Oncology
  PEG-rhG-CSF is a recombinant human granulocyte colony-stimulating factor (G-CSF) conjugated with polyethylene glycol (PEG), which helps stimulate the production of white blood cells.
• Ypeginterferon alfa-2b · Oncology, Infectious Diseases
  Ypeginterferon alfa-2b is a recombinant form of interferon alfa-2b used to modulate the immune system.

Phase 2 pipeline

• Y-shape pegylated somatropin
• YPEG-rhEPO
• YPEG-rhGH

Phase 1 pipeline

• ACT500 tablets
• Pegylated rhEPO
• YPEG-Filgrastim
• YPEG-Somatropin

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Xiamen Amoytop Biotech Co., Ltd. portfolio CI brief
• Xiamen Amoytop Biotech Co., Ltd. pipeline updates RSS